Search
PDS Biotechnology Corp
PDSBAdd to Watchlist
0.853USD
-0.021-2.39%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
46.82MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.39%
5 Days
-3.98%
1 Month
-30.07%
6 Months
+2.39%
Year to Date
+10.82%
1 Year
-35.86%
Key Figures
0.860Open
0.909High
575.84KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.05%Turnover Ratio
0.874Prev. Close
0.820Low
394.74KTurnover
LossP/E Static
5.06P/B
0.00%Div Yield TTM
-93.05%ROA
1.91552wk High
2.61Volume Ratio
-37.61MNet Profit
54.88MShares
-0.6666EPS TTM
1.56Beta
-254.09%ROE
0.50752wk Low
10.16%Amplitude
--Gross Margin
46.82MMarket Cap
-4.66Reward/Risk
6.08%Risk Rate
TradingKey Stock Score of PDS Biotechnology Corp
Currency: USD Updated: 2026-07-02Key Insights
PDS Biotechnology Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 178 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PDS Biotechnology Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
PDS Biotechnology Corp Highlights
StrengthsRisks
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Overvalued
The company’s latest PE is -1.28, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.62M shares, increasing 17.77% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.08.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+758.12%
Upside Space
PDS Biotechnology Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
PDS Biotechnology Corp Info
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Ticker SymbolPDSB
CompanyPDS Biotechnology Corp
CEOBedu-Addo (Frank)
Websitehttps://www.pdsbiotech.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of PDS Biotechnology Corp (PDSB)?
The current price of PDS Biotechnology Corp (PDSB) is 0.85.
What is the symbol of PDS Biotechnology Corp?
The ticker symbol of PDS Biotechnology Corp is PDSB.
What is the 52-week high of PDS Biotechnology Corp?
The 52-week high of PDS Biotechnology Corp is 1.92.
What is the 52-week low of PDS Biotechnology Corp?
The 52-week low of PDS Biotechnology Corp is 0.51.
What is the market capitalization of PDS Biotechnology Corp?
The market capitalization of PDS Biotechnology Corp is 46.82M.
Is PDS Biotechnology Corp (PDSB) currently rated as Buy, Hold, or Sell?
According to analysts, PDS Biotechnology Corp (PDSB) has an overall rating of Buy, with a price target of 7.50.
What is the Earnings Per Share (EPS TTM) of PDS Biotechnology Corp (PDSB)?
The Earnings Per Share (EPS TTM) of PDS Biotechnology Corp (PDSB) is -0.74.